Nicorandil: A potassium channel opening drug for treatment of ischemic heart disease

Journal of Clinical Pharmacology

Volumn 36, Issue 7, 1996, Pages 559-572

  Goldschmidt, Marc ^a   Landzberg, Brian R ^b   Frishman, William H ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; BIMAKALIM; CYCLIC GMP; DILTIAZEM; EMD 56431; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; NICORANDIL; NIFEDIPINE; NITRIC ACID DERIVATIVE; PLACEBO; POTASSIUM CHANNEL STIMULATING AGENT; PROPRANOLOL; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ASTHENIA; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HEADACHE; HEART PALPITATION; HEMODYNAMICS; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; MUSCULOSKELETAL DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; REVIEW; SUBLINGUAL DRUG ADMINISTRATION; VERTIGO;

EID: 0029766082     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04219.x     Document Type: Review

References (83)

1. Taira N: Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989;63:18J-24J.
2. Doring G: Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992;20(suppl 3):S74-S78.
3. Henry PJ, Horowitz JD, Louis WJ: Nitrate intolerance induced by nicorandil or nitroglycerin is associated with minimal loss of nicorandil vasodilatory activity. J Cardiovasc Pharmacol 1990;15: 365-370.
4. Gross GJ, Auchampach JA, Maruyama M, Warltier DC, Pieper GM: Cardioprotective effects of nicorandil. J Cardiovasc Pharmacol 1992;20(suppl 3):S22-S28.
5. Lablanche J-M, Bauters C, Leroy F, Bertrand ME: Prevention of coronary spasm by nicorandil: comparison with nifedipine. J Cardiovasc Pharmacol 1992;20(suppl 3):S82-S85.
6. Ferguson PB: Potassium channels. In, Izzo JL, Black HR (eds): Hypertension Primer of the American Heart Association. Dallas, TX: American Heart Association, 1993;38-39.
7. Cook NS: The pharmacology of potassium channels and their therapeutic potential. Trends Pharmacol Sci 1988;9:21-28.
8. Standen NB, Quayle JM, Davies NW, Brayden JE, Huang Y, Nelson MT: Hyperpolarizing vasodilators activate ATP sensitive potassium channels in arterial smooth muscle. Science 1989;245: 177-180.
9. Atwal KS: Pharmacology and structure activity relationships for KATP modulators-tissue selective KATP openers. J Cardiovasc Pharmacol 1994;24(suppl 4):S12-S17.
10. Kukovetz WR, Holzmann S, Poch G: Molecular mechanism of action of nicorandil. J Cardiovasc Pharmacol 1992;20(suppl 3):S1-S7.
11. Holzmann S: Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75). J Cardiovasc Pharmacol 1983;5:364-370.
12. Schmidt K, Reich R, Kukovetz WR: Stimulation of coronary guanylate cyclase by nicorandil (SG-75) as a mechanism of its vasodilating action. J Cyclic Nucleotide Protein Phosphorylation Res 1985;10:43-53.
13. Waldman SA, Murad F: Cyclic GMP synthesis and function. Pharmacol Rev 1987;39:163-196.
14. Morimoto S, Koh E, Fukuo K, Imanaka S, Hironaka T, Shiraishi T, et al: Effect of nicorandil on the cytosolic free calcium concentration and microsomal (Ca + Mg)-ATPase activity of vascular smooth muscle cells. J Cardiovasc Pharmacol 1987;10(suppl 8): S31-S38.
15. 86Rb efflux and isometric vasorelaxation studies in vascular smooth muscle. J Cardiovasc Pharmacol 1992;20(suppl 3):S8-S12.
16. Daut J, Maier-Rudolph W, von Beckerath N, Mehrke G, Gunther K, Goedel-Meinen L: Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 1990;247:1341-1344.
17. Robertson BE, Schubert R, Hescheler J, Nelson MT: cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells. Am J Physiol 1993;265:C299-C303.
18. Opie LH: The Heart: Physiology and Metabolism. Second edition. New York: Raven Press, 1991.
19. Taylor SG, Weston AG: Endothelium-derived hyperpolarizing factor: a new endogenous inhibitor from the vascular endothelium. Trends Pharmacol 1988;9:272-274.
20. Furukawa K, Itoh T, Kajiwara M, Kitamura K, Suizuki H, Ito Y, Kuriyama H: Vasodilating actions of 2-nicotinamide ethyl nitrate on porcine and guinea pig coronary arteries. J Pharmacol Exp Ther 1981;218:248-259.
21. Hamilton TC, Buckingham RE, Clapham JC, Coldwell MC, Howlett DR, Wilson C: BRL 3495, a novel antihypertensive agent with potassium channel activity properties. Cardiovasc Drugs Ther 1987;1:244.
22. Imanishi S, Arita M, Kiyosue T, Aomine M: Effects of SG-75 (nicorandil) on electrical activity of canine cardiac Purkinje fibers: possible increase in potassium conductance. J Pharmacol Exp Ther 1983;225:198-205.
23. Kakei M, Yoshinaga M, Saito K, Tanaka H: The potassium current activated by 2-nicotinamidoethyl nitrate (nicorandil) in single ventricular cells of guinea pigs. Prog R Soc London 1986;229: 331-343.
24. Waters DD, Szlachcic J, Theroux P, Dauwe F, Mizgala HF: Ergonovine testing to detect spontaneous remission of variant angina during long-term treatment with calcium antagonist drugs. Am J Cardiol 1981;47:179-184.
25. Yanagisawa T, Taira N: Effect of 2-nicotinamidothyl nitrate (SG-75) on the membrane potential of left atrial muscle fibres of the dog. Naunym Schmiedebergs Arch Pharmacol 1980;312:69-76.
26. Yanagisawa T, Taira: Effect of 2-nicotinamidoethyl nitrate (SG-75) on membrane potentials of canine Purkinje fibres. Jpn J Pharmacol 1980;31:409-417.
27. Allen SL, Boyle JP, Cortijo J, Foster RW, Morgan GP, Small RC: Electrical and mechanical effects of BRL 3495 in guinea pig isolated trachealis. Br J Pharmacol 1986;89:395-405.
28. Inoue R, Ito Y, Takeda T: The effects of 2-nicotinamidoethyl nitrate on smooth muscle cells of the dog mesenteric artery and trachea. Br J Pharmacol 1983;80:459-470.
29. Frydman A: Pharmacokinetic profile of nicorandil in humans: an overview. J Cardiovasc Pharmacol 1992;20(suppl 3):S34-S44.
30. Frydman AM, Chapelle P, Diekmann H, Bruno R, Thebault JJ, Bouthier J, et al: Pharmacokinetics of nicorandil. Am J Cardiol 1989;63:25J-33J.
31. Hashimoto K, Kinoshita M, Ohbayashi Y: Coronary effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs. Cardiovasc Drugs Ther 1991;5:131-138.
32. Kinoshita M, Sakai K: Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther 1990;4:1075-1088.
33. Lamping KA, Gross GJ: Comparative effects of a new nicotinamide nitrate derivative, nicorandil (SG-75), with nifedipine and nitroglycerin on true collateral blood flow following an acute coronary occlusion in dogs. J Cardiovasc Pharmacol 1984;6:601-608.
34. Huckstorf C, Bassenge E: Effects of long-term nicorandil application on coronary arteries in conscious dogs. J Cardiovasc PharmacoJ 1992;20(suppl 3):S29-S33.
35. Munzel T, Huckstorf C, Bassenge E: Effects of long-term sydnonimine infusion on endothelium-dependent and independent vasodilation of large coronary arteries (abstract). FASEB J 1991;5: A1729.
36. Stewart DJ, Holtz J, Bassenge E: Long-term nitroglycerine treatment: effect on direct and endothelium-mediated large coronary artery dilation in conscious dogs. Circulation 1987;75:847-856.
37. Tsutamoto T, Kinoshita M, Hisanaga T, Maeda Y, Maeda K, Wada A, et al: Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. Am J Cardiol 1995;75: 1162-1165.
38. Bachert EL, Fung HL: Hemodynarnic tolerance and pharmacokinetics of nicorandil in experimental heart failure. J Cardiovasc Pharmacol 1993;21:781-785.
39. Berdeaux A, Brieu la Rochelle C, Richard V, Giudicelli JF: Differential effects of nitrovasodilators, K-channel openers, and nicorandil on large and small coronary arteries in conscious dogs. J Cardiovasc Pharmacol 1992;20(suppl 3):S17-S21.
40. Cox DA, Vita JA, Treasure CB, Fish D, Alexander RW, Ganz P, Selwyn AP: Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989;80:458-465.
41. Nabel EG, Selwyn AP, Ganz P: Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol 1990;16:349-356.
42. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP: Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 1988;77:43-52.
43. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-1051.
44. Olesen S, Claplan DE, Davies PF: Hemodynamic shear stress activates a potassium current in vascular endothelial cells. Nature 1988;331:168-170.
45. Lamping KA, Gross GJ: Improved recovery of myocardial segment function following a short coronary occlusion in dogs by nicorandil, a potent new antianginal agent, and nifedipine. J Cardiovasc Pharmacol 1985;7:158-166.
46. Lamping KA, Christensen CW, Pelc LR, Warltier DC, Gross GJ: Effects of nicorandil and nifedipine on protection of ischemic myocardium. J Cardiovasc Pharmacol 1984;6:536-542.
47. Belz GG, Matthews JH, Beck A, Wagner G, Schneider B: Hemodynamic effects of nicorandil, isosorbide dinitrate and hydralazine in healthy volunteers. J Cardiovasc Pharmacol 1985;7:1107-1112.
48. Belz GG, Matthews JH, Heinrich J, Wagner G: Controlled comparison of the pharmacodynamic effects of nicorandil (SG-75) and isosorbide dinitrate in man. Eur J Clin Pharmacol 1984;26:681-685.
49. Belz GG, Beermann C: Venodilatory effects of nicorandil in healthy volunteers. J Cardiovasc Pharmacol 1992;20(suppl 3):S57-S58.
50. Coltart DJ, Signy M: Acute hemodynamic effects of single-dose nicorandil in coronary heart disease. Am J Cardiol 1989;63:34J-39J.
51. Murakami M, Takeyama Y, Matsubara H, Hasegawa S, Nakamura M, Sekita S, Katagiri T: Effects of intravenous injection of nicorandil on systemic and coronary hemodynamics in patients with old myocardial infarction: a comparison with nifedipine and isosorbide dinitrate (abstract). Eur Heurt J 1989;10(suppl 1):426.
52. Cohen-Solal A, Jaeger P, Bouthier J, Juliard JM, Dahan M, Gourgon R: Hemodynamic action of nicorandil in chronic congestive heart failure. Am J Cardiol 1989;63:44J-48J.
53. Tice FD, Binkley PF, Cody RJ, Moeschberger MI, Mohrland JS, Wolf DL, Leier CV: Hemodynamic effects of oral nicorandil in congestive heart failure. Am J Cardiol 1990;65:1361-1367.
54. Verdouw PD, Sassen LMA, Duncker DJ, Schmeets IOL, Rensen RJ, Saxena PR: Nicorandil-induced changes in the distribution of cardiac output and coronary blood flow in pigs. Naunyn Schmiedebergs Arch Pharmacol 1987;336:352-358.
55. Bossaller C, Auch-Schwelk W, Graf K, Grafe M, Catadelgirmen G, Ennker J, Fleck E: Relaxation of human coronary artery and arteria mammaria by K+-channel openers. J Cardiovasc Pharmacol 1992;20(suppl 3):S13-S16.
56. Thormann J, Schlepper M, Kramer W, Gottwik M, Kindler M: Effectiveness of nicorandil (SG-75), a new long-acting drug with nitroglycerin effects, in patients with coronary artery disease: improved left ventricular function and regional wall motion and abolition of pacing-induced angina. J Cardiovasc Pharmacol 1983;5: 371-377.
57. Minamiji K, Kurogane H, Fujino M, Yoshida Y: Hemodynamic effects of intravenous nicorandil: comparison with nitroglycerin (abstract). Eur Heart J 1989;10:74.
58. Mitrovic V, Neuss H, Kindler M: Elektrophysiologische auwirkungen einer vasodilation durch nicorandil. Herz/Kreisl 1986;18:403-407.
59. Suryapranata H, MacLeod D: Nicorandil and cardiovascular performance in patients with coronary artery disease. J Cardiovasc Pharmacol 1992;20(suppl 3):S45-S51.
60. Ohnishi M, Maeda K, Fukuzaki W, et al: Antianginal mechanism of nicorandil: study on exercise invasive hemodynamics and thallium-201 myocardial perfusion images. J Jpn Coll Angiol 1987;27:191-195.
61. Kambara H, Nakamura Y, Tamaki S, Kawai C: Beneficial effects of nicorandil on cardiovascular hemodynamics and left ventricular function. Am J Cardiol 1989;53:56J-60J.
62. Lamping KA, Warltier DC, Hardman HF, Gross GJ: Effects of nicorandil, a new antianginal agent, and nifedipine on collateral blood flow in chronic coronary occlusion model. J Pharmacol Exp Ther 1984;229:359-363.
63. Kobayashi K, Hakuta T: Effects of nicorandil on coronary hemodynamics in ischaemic heart disease: comparison with nitroglycerin, nifedipine, and propranolol. J Cardiovasc Pharmacol 1987;10(suppl 8):S109-S115.
64. Hongo M, Takenaka H, Uchikawa S, Nakatsuka T, Watanabe N, Sekiguchi M: Coronary microvascular response to intracoronary administration of nicorandil. Am J Cardiol 1995;75:246-250.
65. Suryapranata H, Serruys PW: Coronary vasodilation action after nicorandil: a quantitative angiographic study. Am J Cardiol 1989;63:80J-85J.
66. Wagner G: Selected issues from an overview on nicorandil: tolerance, duration of action, and long-term efficacy. J Cardiovasc Pharmacol 1992;20(suppl 3):S86-S92.
67. Wagner F, Heberer C, Sprock C, Trenk D, Jahnchen E: Lack of effect of molsidomine in the state of hemodynamic tolerance to organic nitrates (abstract). Eur Heart J 1988;9(suppl 1):173.
68. Wagner F, Siefert F, Trenk D, Jahnchen E: Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate. Eur J Clin Pharmacol 1990;39:S53-S59.
69. Tabone X, Funck-Brentano C, Billon N, Jaillon P: Comparison of tolerance to intravenous nitroglycerin during nicorandil and intermittent nitroglycerin patch in healthy volunteers. Clin Pharmacol Ther 1994;56:672-679.
70. Kinoshita M, Hashimoto K, Ohbayashi Y, Inoue T, Taguchi H, Mitsunami K: Comparison of antianginal activity of nicorandil, propranolol and diltiazem with reference to the antianginal mechanism. Am J Cardiol 1989;63:71J-74J.
71. Falcone C, Auguadro C, Chioffi M, Bokor D, Palagi L, Specchia G: A double-blind comparison of nicorandil and isosorbide dinitrate slow release in patients with stable angina pectoris (abstract). Eur Heart J 1993;14(suppl 1):376.
72. Camm AJ, Maltz MB: A controlled single-dose study of the efficacy, dose response, and duration of action of nicorandil in angina pectoris. Am J Cardiol 1989;63:61J-65J.
73. Meany TB, Richardson P, Camm AJ, Coltart J, Griffith M, Maltz MB, Signy M: Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. Am J Cardiol 1989;63:66J-70J.
74. Meeter K, Kelder JC, Tijssen JGP, Bucx JJJ, Henneman JA, Kerker JP, Hugenholtz PG: Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. J Cardiovasc Pharmacol 1992;20(suppl 3):S59-S66.
75. Ulvenstam F, Diderholm E, Frithz G, Gudbrandsson T, Hedback B, Hoglund C, et al: Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol 1992;20(suppl 3):S67-S73.
76. Thadani U, Strauss W, Glasser SP, Frishman WH, Burger AJ, Locker PK, Mohrland JS: Evaluation of antianginal and anti-ischemic efficacy of nicorandil: results of a multicenter study (abstract). J Am Coll Cardiol 1994;23(suppl A):276A.
77. Bertrand ME, LaBlanche JM, Tilmant PY, Thieuleux FA, Delforge MR, Carre AG, et al: Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. Circulation 1982;65:1299-1306.
78. Previtali M, Panciroli C, DePonti R, Chimienti M, Montemartini C, Salerno JA: Time-related decrease in sensitivity to ergonovine in patients with variant angina. Am Heart J 1989;117:92-99.
79. Theroux P, Waters DD, Affaki GS, Crittin J, Bonan R, Mizgala HF: Provocative testing with ergonovine to evaluate the efficacy of treatment with calcium antagonists in variant angina. Circulation 1979;60:504-510.
80. Thieuleux F, Lablanche JM, Delmotte C, Bertrand ME: Provoked coronary arterial spasm: comparison of four provocative tests (abstract). Eur Heart J 1983;4(suppl E):45.
81. Waters DD, Theroux P, Szlachcic J, Dauwe P: Provocative testing with ergonovine to assess the efficacy of treatment with nifedipine, diltiazem and verapamil in variant angina. Am J Cardiol 1981;48:123-130.
82. Curry RC, Pepine CJ, Sabom MB, Conti CR: Similarities of ergonovine-induced and spontaneous attacks of variant angina. Circulation 1979;52:307-312.
83. Aizawa T, Ogasawara K, Nakamura F, Hirosaka A, Sakuma T, Nagashima K, Kato K: Effect of nicorandil on coronary spasm. Am J Cardiol 1989;63:75J-79J.